아나필락시스 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Anaphylaxis Market - Scope of Report

TMR's report on the global anaphylaxis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global anaphylaxis market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anaphylaxis market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anaphylaxis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anaphylaxis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anaphylaxis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anaphylaxis market.

The report delves into the competitive landscape of the global anaphylaxis market. Key players operating in the global anaphylaxis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anaphylaxis market profiled in this report.

Key Questions Answered in global anaphylaxis Market Report:

• What is the sales/revenue generated by anaphylaxis across all regions during the forecast period?
• What are the opportunities in the global anaphylaxis market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Anaphylaxis Market - Research Objectives and Research Approach

The comprehensive report on the global anaphylaxis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anaphylaxis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anaphylaxis market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anaphylaxis Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Anaphylaxis Market Analysis and Forecasts, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure across Key Regions / Countries
• 5.2. Technological Advancements in Anaphylaxis Management
• 5.3. Epidemiology of Anaphylaxis across Key Regions / Countries
• 5.4. Regulatory Scenario across Key Regions / Countries
• 5.5. PORTER's Five Forces Analysis
• 5.6. PESTEL Analysis
• 5.7. Value Chain Analysis
• 5.8. Key Purchase Metrics for End-users
• 5.9. Go-to-Market Strategy for New Market Entrants
• 5.10. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
• 5.11. Benchmarking of Products Offered by the Leading Competitors

6. Global Anaphylaxis Market Analysis and Forecasts, By Drug Class

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Class, 2020-2035
  • 6.3.1. Epinephrine
  • 6.3.2. Antihistamines
  • 6.3.3. Others
• 6.4. Market Attractiveness By Drug Class

7. Global Anaphylaxis Market Analysis and Forecasts, By Dosage Form

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Dosage Form, 2020-2035
  • 7.3.1. Injectables
  • 7.3.2. Tablets / Capsules
  • 7.3.3. Others
• 7.4. Market Attractiveness By Dosage Form

8. Global Anaphylaxis Market Analysis and Forecasts, By Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Route of Administration, 2020-2035
  • 8.3.1. Intramuscular Injection
  • 8.3.2. Subcutaneous Injection
  • 8.3.3. Oral
  • 8.3.4. Others
• 8.4. Market Attractiveness By Route of Administration

9. Global Anaphylaxis Market Analysis and Forecasts, By Drug Type

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Drug Type, 2020-2035
  • 9.3.1. Branded
  • 9.3.2. Generic
• 9.4. Market Attractiveness By Drug Type

10. Global Anaphylaxis Market Analysis and Forecasts, By Distribution Channel

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Distribution Channel, 2020-2035
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness By Distribution Channel

11. Global Anaphylaxis Market Analysis and Forecasts, By Region

• 11.1. Key Findings
• 11.2. Market Value Forecast By Region
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness By Region

12. North America Anaphylaxis Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Drug Class, 2020-2035
  • 12.2.1. Epinephrine
  • 12.2.2. Antihistamines
  • 12.2.3. Others
• 12.3. Market Value Forecast By Dosage Form, 2020-2035
  • 12.3.1. Injectables
  • 12.3.2. Tablets / Capsules
  • 12.3.3. Others
• 12.4. Market Value Forecast By Route of Administration, 2020-2035
  • 12.4.1. Intramuscular Injection
  • 12.4.2. Subcutaneous Injection
  • 12.4.3. Oral
  • 12.4.4. Others
• 12.5. Market Value Forecast By Drug Type, 2020-2035
  • 12.5.1. Branded
  • 12.5.2. Generic
• 12.6. Market Value Forecast By Distribution Channel, 2020-2035
  • 12.6.1. Hospital Pharmacies
  • 12.6.2. Retail Pharmacies
  • 12.6.3. Online Pharmacies
• 12.7. Market Value Forecast By Country, 2020-2035
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Drug Class
  • 12.8.2. By Dosage Form
  • 12.8.3. By Route of Administration
  • 12.8.4. By Drug Type
  • 12.8.5. By Distribution Channel
  • 12.8.6. By Country

13. Europe Anaphylaxis Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Class, 2020-2035
  • 13.2.1. Epinephrine
  • 13.2.2. Antihistamines
  • 13.2.3. Others
• 13.3. Market Value Forecast By Dosage Form, 2020-2035
  • 13.3.1. Injectables
  • 13.3.2. Tablets / Capsules
  • 13.3.3. Others
• 13.4. Market Value Forecast By Route of Administration, 2020-2035
  • 13.4.1. Intramuscular Injection
  • 13.4.2. Subcutaneous Injection
  • 13.4.3. Oral
  • 13.4.4. Others
• 13.5. Market Value Forecast By Drug Type, 2020-2035
  • 13.5.1. Branded
  • 13.5.2. Generic
• 13.6. Market Value Forecast By Distribution Channel, 2020-2035
  • 13.6.1. Hospital Pharmacies
  • 13.6.2. Retail Pharmacies
  • 13.6.3. Online Pharmacies
• 13.7. Market Value Forecast By Country / Sub-region, 2020-2035
  • 13.7.1. Germany
  • 13.7.2. U.K.
  • 13.7.3. France
  • 13.7.4. Spain
  • 13.7.5. Italy
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Drug Class
  • 13.8.2. By Dosage Form
  • 13.8.3. By Route of Administration
  • 13.8.4. By Drug Type
  • 13.8.5. By Distribution Channel
  • 13.8.6. By Country / Sub-region

14. Asia Pacific Anaphylaxis Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Class, 2020-2035
  • 14.2.1. Epinephrine
  • 14.2.2. Antihistamines
  • 14.2.3. Others
• 14.3. Market Value Forecast By Dosage Form, 2020-2035
  • 14.3.1. Injectables
  • 14.3.2. Tablets / Capsules
  • 14.3.3. Others
• 14.4. Market Value Forecast By Route of Administration, 2020-2035
  • 14.4.1. Intramuscular Injection
  • 14.4.2. Subcutaneous Injection
  • 14.4.3. Oral
  • 14.4.4. Others
• 14.5. Market Value Forecast By Drug Type, 2020-2035
  • 14.5.1. Branded
  • 14.5.2. Generic
• 14.6. Market Value Forecast By Distribution Channel, 2020-2035
  • 14.6.1. Hospital Pharmacies
  • 14.6.2. Retail Pharmacies
  • 14.6.3. Online Pharmacies
• 14.7. Market Value Forecast By Country / Sub-region, 2020-2035
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Drug Class
  • 14.8.2. By Dosage Form
  • 14.8.3. By Route of Administration
  • 14.8.4. By Drug Type
  • 14.8.5. By Distribution Channel
  • 14.8.6. By Country / Sub-region

15. Latin America Anaphylaxis Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Drug Class, 2020-2035
  • 15.2.1. Epinephrine
  • 15.2.2. Antihistamines
  • 15.2.3. Others
• 15.3. Market Value Forecast By Dosage Form, 2020-2035
  • 15.3.1. Injectables
  • 15.3.2. Tablets / Capsules
  • 15.3.3. Others
• 15.4. Market Value Forecast By Route of Administration, 2020-2035
  • 15.4.1. Intramuscular Injection
  • 15.4.2. Subcutaneous Injection
  • 15.4.3. Oral
  • 15.4.4. Others
• 15.5. Market Value Forecast By Drug Type, 2020-2035
  • 15.5.1. Branded
  • 15.5.2. Generic
• 15.6. Market Value Forecast By Distribution Channel, 2020-2035
  • 15.6.1. Hospital Pharmacies
  • 15.6.2. Retail Pharmacies
  • 15.6.3. Online Pharmacies
• 15.7. Market Value Forecast By Country / Sub-region, 2020-2035
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Drug Class
  • 15.8.2. By Dosage Form
  • 15.8.3. By Route of Administration
  • 15.8.4. By Drug Type
  • 15.8.5. By Distribution Channel
  • 15.8.6. By Country / Sub-region

16. Middle East & Africa Anaphylaxis Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Drug Class, 2020-2035
  • 16.2.1. Epinephrine
  • 16.2.2. Antihistamines
  • 16.2.3. Others
• 16.3. Market Value Forecast By Dosage Form, 2020-2035
  • 16.3.1. Injectables
  • 16.3.2. Tablets / Capsules
  • 16.3.3. Others
• 16.4. Market Value Forecast By Route of Administration, 2020-2035
  • 16.4.1. Intramuscular Injection
  • 16.4.2. Subcutaneous Injection
  • 16.4.3. Oral
  • 16.4.4. Others
• 16.5. Market Value Forecast By Drug Type, 2020-2035
  • 16.5.1. Branded
  • 16.5.2. Generic
• 16.6. Market Value Forecast By Distribution Channel, 2020-2035
  • 16.6.1. Hospital Pharmacies
  • 16.6.2. Retail Pharmacies
  • 16.6.3. Online Pharmacies
• 16.7. Market Value Forecast By Country / Sub-region, 2020-2035
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Drug Class
  • 16.8.2. By Dosage Form
  • 16.8.3. By Route of Administration
  • 16.8.4. By Drug Type
  • 16.8.5. By Distribution Channel
  • 16.8.6. By Country / Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 17.2. Market Share Analysis By Company (2024)
• 17.3. Company Profiles
  • 17.3.1. Viatris Inc.
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. Pfizer Inc.
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. Teva Pharmaceutical Industries Ltd.
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. Fresenius Kabi AG
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. Kaleo, Inc.
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. ARS Pharmaceuticals, Inc.
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. Mylan N.V.
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. Glenmark Pharmaceuticals
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Bryn Pharma
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. Aquestive Therapeutics, Inc.
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. Endo, Inc.
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments
  • 17.3.12. DMK Pharmaceuticals Corporation
    • 17.3.12.1. Company Overview
    • 17.3.12.2. Financial Overview
    • 17.3.12.3. Product Portfolio
    • 17.3.12.4. Business Strategies
    • 17.3.12.5. Recent Developments
  • 17.3.13. ALK-Abello A/S
    • 17.3.13.1. Company Overview
    • 17.3.13.2. Financial Overview
    • 17.3.13.3. Product Portfolio
    • 17.3.13.4. Business Strategies
    • 17.3.13.5. Recent Developments
  • 17.3.14. Amneal Pharmaceuticals LLC
    • 17.3.14.1. Company Overview
    • 17.3.14.2. Financial Overview
    • 17.3.14.3. Product Portfolio
    • 17.3.14.4. Business Strategies
    • 17.3.14.5. Recent Developments
  • 17.3.15. Grand Pharma (China) Co., Ltd.
    • 17.3.15.1. Company Overview
    • 17.3.15.2. Financial Overview
    • 17.3.15.3. Product Portfolio
    • 17.3.15.4. Business Strategies
    • 17.3.15.5. Recent Developments